Submit Deal

Announced

17 Jul 2023

Completed

31 Aug 2023

MediPacific completed the acquisition of Pardes Biosciences for $125m.

Synopsis

MediPacific completed the acquisition of Pardes Biosciences, a company that has focused on discovering, developing and commercializing novel oral antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, for $125m.

Principals

target

Pardes Biosciences

bidder

Medipacific

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (12)

ethan skerry

Partner at Fenwick & West

Lawyer

target

Deals

£ 17.36 B

Total Value

douglas cogen

Partner at Fenwick & West

Lawyer

target

Deals

£ 90.49 B

Total Value

jeremy delman

Counsel at Fenwick & West

Lawyer

target

Deals

£ 790 M

Total Value

matthew reiser

Associate at Fenwick & West

Lawyer

target

Deals

£ 24.70 B

Total Value

philip ewing

Associate at Fenwick & West

Lawyer

target

Deals

£ 10.33 B

Total Value

ran ben-tzur

Partner at Fenwick & West

Lawyer

target

Deals

£ 40.79 B

Total Value

jennifer hitchcock

Partner at Fenwick & West

Lawyer

target

Deals

£ 31.96 B

Total Value

joshua w. damm

Associate at Fenwick & West

Lawyer

target

Deals

£ 3.20 B

Total Value

beth clarke

Associate at Fenwick & West

Lawyer

target

Deals

£ 15.31 B

Total Value

marguerite moloney

Associate at Fenwick & West

Lawyer

target

Deals

£ 3.96 B

Total Value

michael knobler

Associate at Fenwick & West

Lawyer

target

Deals

£ 31.29 B

Total Value

key shin

Partner at Fenwick & West

Lawyer

target

Deals

£ 702 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy